temazepam
Adjunctive therapy • Brands: RESTORIL
Last reviewed: 2025-12-29
General information
- Class: Adjunctive therapy
- Common US brands: RESTORIL
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2025-12-29
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Benzodiazepine hypnotic; GABA-A receptor positive allosteric modulator.
Metabolism & Half‑life
- Metabolism: Glucuronidation
- Half‑life: Single-dose mean 8.8 h; Single-dose range 3.5–18.4 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- Restoril (temazepam) prescribing information — DailyMed (2024)
- Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline — Journal of Clinical Sleep Medicine (2017)
- ASAM guideline on benzodiazepines — Journal of Addiction Medicine (2020)
- Efficacy and Acceptability of Pharmacological Interventions for Insomnia in Patients With Severe Mental Illness — Acta Psychiatrica Scandinavica (2025)
- Residual effects of medications for sleep disorders on driving performance — European Neuropsychopharmacology (2024)